Batra Sandeep, MBBS
Clinical Assistant Professor of Pediatrics
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202
Pediatric Hematology Oncology
Areas of Interest
Pediatric Leukemias and solid tumor biology, clinical trials involving new agents.
I have been in clinical practice for several years and have a strong background in treating pediatric cancers of all kinds. My current research focus is to investigate and define the biological role of Ref-1 in relapsed, drug-refractory childhood ALL, and translate lab findings from pre-clinical studies into Phase-I/II clinical trials in refractory or recurrent pediatric ALL.
|1987||BS, Dehli University, India|
|1992||MB, Dehli University, India|
|1979-1982||2003, Fellowship, Children's Hospital of Los Angeles|
Honors & Awards
- 2000 Outstanding Resident Research Award, Suffolk Pediatric Society, NY
- 2001 Fasanelli Research Award nominee for best scientific study, Society of International Pediatric Oncology (SIOP)
- 2001 Childrens Cancer Research Foundation (CCRF) Fellow
Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
Research & Grants
T-cell lineage acute lymphoblastic leukemia (ALL) is a uncommon but potentially lethal type of blood cancer that affects children. Although conventional treatments are successful in most children with T-cell ALL, leukemia relapse and drug-resistance remain significant clinical challenges. Therefore, novel therapies are needed for T-ALL that recurs after conventional treatment. My collaborators – Drs Mark Kelley and Angelo Cordoso have identified a protein pathway (Ref-1) that may play an important role in drug resistance and disease relapse in T-ALL. As a collaborator, I will be one of the lead clinical investigators responsible for testing Ref-1 inhibitors in patients with T-ALL.
We received the $250,000 Hyundai Hope Grant for pediatric cancer research in 2013 to conduct preclinical studies aimed at understanding the role of Ref-1 in childhood leukemias.
Batra S, Perelman N, Luck L, Shimada H and Malik P. Erythropoietin and functional erythropoietin receptor in pediatric solid tumors. Lab Inv, 83: 1477-1488, 2003.
Batra, S, Reynolds CP, Maurer BJ. Fenretinide Cytotoxicity for Ewing’s Sarcoma (ES) and Primitive Neuroectodermal Tumor (PNET) Cell Lines is decreased by Hypoxia and Synergistically Enhanced by Ceramide Modulators. Cancer Res. 2004 Aug 1; 64(15):5415-24.
Goldman S, Tadanori T, Marymont M, Kalapurakal J, Batra S, Gleason T, Newmark M, Weinsten J, Bendel A, Hyder D, Kletzel M, Keating G and Cohen K. Thalidomide and Carboplatin for the treatment of brain stem glioma, Proceedings of ISPNO, 2004
Failing J, Dorsam S, Hermann R, Batra S and Dorsam G. Can neuropeptide receptors really cause leukemogenesis? FASEB J. 2010 24:833.9
Dorsam GP, Benton K, Failing J, Batra S. Vasoactive intestinal peptide signaling axis in human leukemia. World J Biol Chem. 2011 Jun 26;2(6):146-60
Ding J, Luo M, Czader M, Reese R, Batra S, Carlesso N, Fishel M, Kelley M, and Cardoso AA. Ref-1 is master regulator of leukemia T-cell survival, and a new therapeutic target for relapsed childhood acute lymphoblastic leukemia. Midwest Blood Club Symposium, 2012
Batra S. Current treatment of Wilms Tumor. Br. J .Med/Epocrates 2014